image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Alliance Pharma

November 2011

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • APH
  • Price:
  • 31p
Alliance Pharma, which owns a portfolio of branded generic medicines, produced a 17% increase in half year pretax profit to £7m on sales ahead 3% to £24.4m. The decent growth came despite increased competition for Deltacortril, one of its top-selling drugs but its dermatology and oncology portfolios performed well. Net debt increased slightly by £0.7m to £17.7m but net debt to EBITDA remains low at 0.9 times. Continuing its policy of using cash flow to fund bolt-on eps enhancing acquisitions, Alliance has just purchased six products from Beacon Pharmaceuticals for £2.4m, which had made a gross profit of £0.9m in the 12 months to April on sales of £2m. The majority of sales come from Rizude ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Alliance Pharma (July 2013)
Alliance Pharma - Acquires new products (September 2012)
Alliance Pharma (June 2012)
Alliance Pharma - Cambridge Labs nehind its growth (June 2011)
Alliance Pharma (October 2010)
Alliance Pharma (August 2010)
Alliance Pharma - Trading ahead of expectations (July 2010)
Alliance Pharma - Gain reaches 75% in five months (May 2010)
Alliance Pharma - Substantial eps enhancing acquisition (March 2010)
Alliance Pharma - Beats expectations again (February 2010)
Alliance Pharma - Branded pharmaceuticals firm going great guns but cheap on PE of 6.7 (December 2009)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X